Major Adverse Dystrophinopathy Event Score as Marker of Cumulative Morbidity and Risk for Mortality in Boys with Duchenne Muscular Dystrophy

[1]  E. Pegoraro,et al.  Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. , 2022, The Lancet. Respiratory medicine.

[2]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[3]  K. Kinnett,et al.  Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION , 2022, Pediatric Cardiology.

[4]  A. Fernandez-Fernandez,et al.  The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD , 2021, Journal of neuromuscular diseases.

[5]  J. Teuteberg,et al.  The Stanford acute heart failure symptom score for patients hospitalized with heart failure. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  C. Almond,et al.  The Creation of a Pediatric Health Care Learning Network: The ACTION Quality Improvement Collaborative , 2020, ASAIO journal.

[7]  N. Jahan,et al.  Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review , 2019, Cureus.

[8]  S. Nelson,et al.  Cardiac MRI biomarkers for Duchenne muscular dystrophy , 2018, Biomarkers in medicine.

[9]  A. Pestronk,et al.  Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids , 2017, Neuromuscular Disorders.

[10]  Carla M Bann,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management , 2018, The Lancet Neurology.

[11]  E. Hoffman,et al.  Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study , 2017, The Lancet.

[12]  M. Desai,et al.  Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  G. Kolovou,et al.  Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. , 2018, Methods in molecular biology.

[14]  M. Drazner,et al.  Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy , 2017, Journal of the American Heart Association.

[15]  Paul J. Wang,et al.  Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. , 2017, Circulation.

[16]  R. Finkel,et al.  Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[17]  W. Hung,et al.  The burden of major adverse cardiac events in patients with coronary artery disease , 2017, BMC Cardiovascular Disorders.

[18]  K. Bushby,et al.  Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[19]  B. Byrne,et al.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.

[20]  P. Gilbert,et al.  Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition , 2015, Journal of causal inference.

[21]  C. Angelini.  Prevention of cardiomyopathy in Duchenne muscular dystrophy , 2015, The Lancet Neurology.

[22]  Carmen Cadarso-Suárez,et al.  OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests , 2014 .

[23]  J. Waltenberger,et al.  Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients , 2014, Journal of Cardiovascular Magnetic Resonance.

[24]  C. Spurney,et al.  Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy , 2014, Muscle & nerve.

[25]  Jay J. Han,et al.  The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.

[26]  Jay J. Han,et al.  The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used , 2013, Muscle & nerve.

[27]  D. Bernstein,et al.  Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy. , 2013, The American journal of emergency medicine.

[28]  C. Spurney.  Cardiomyopathy of duchenne muscular dystrophy: Current understanding and future directions , 2011, Muscle & nerve.

[29]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[30]  M. Gonen,et al.  Concordance probability and discriminatory power in proportional hazards regression , 2005 .

[31]  G. Corrado,et al.  Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. , 2002, The American journal of cardiology.

[32]  E. Mattsson,et al.  Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. , 2001, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[33]  Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. , 1999, Chest.

[34]  J. Miller,et al.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. , 1989, The New England journal of medicine.